Citigroup Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation
Fintel reports that on May 18, 2026, Citigroup initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Buy recommendation.
Analyst Price Forecast Suggests 101.45% Upside
As of May 14, 2026, the average one-year price target for Korro Bio is $20.14/share. The forecasts range from a low of $8.08 to a high of $31.50. The average price target represents an increase of 101.45% from its latest reported closing price of $10.00 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Korro Bio is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.07.
What is the Fund Sentiment?
There are 108 funds or institutions reporting positions in Korro Bio. This is an decrease of 42 owner(s) or 28.00% in the last quarter. Average portfolio weight of all funds dedicated to KRRO is 0.14%, an increase of 52.14%. Total shares owned by institutions increased in the last three months by 67.12% to 13,271K shares. 
The put/call ratio of KRRO is 0.53, indicating a bullish outlook.
What are Other Shareholders Doing?
Lynx1 Capital Management holds 1,538K shares representing 10.67% ownership of the company. In its prior filing, the firm reported owning 678K shares , representing an increase of 55.93%. The firm increased its portfolio allocation in KRRO by 150.38% over the last quarter.
NEA Management Company holds 1,298K shares representing 9.00% ownership of the company. In its prior filing, the firm reported owning 1,091K shares , representing an increase of 15.96%. The firm increased its portfolio allocation in KRRO by 87.46% over the last quarter.
Atlas Venture Life Science Advisors holds 1,137K shares representing 7.88% ownership of the company. No change in the last quarter.
Balyasny Asset Management holds 1,040K shares representing 7.21% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
VR Adviser holds 1,010K shares representing 7.00% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.